The purpose of this study is to evaluate the efficacy of thymosin alpha 1 for treating severe sepsis.
Severe sepsis is a disease of infectious origin with a high risk of death. Over the past decade, thymosin alpha1 have already provided clinicians with additional weapon in the fight against infectious diseases, but it is unknown whether thymosin alpha1 is effective in treating severe sepsis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
366
1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
Sun Yat-sen University
Guangzhou, Guangdong, China
28-day Mortality
The prospectively defined primary end point was death from any cause and was assessed 28 days after the start of the infusion.
Time frame: 28 days
SOFA score
SOFA score was measured on day0, 3 and 7 after the start of the infusion in both groups.
Time frame: 7 days
Immune response to Thymosin alpha 1
HLA-DR expression on CD14+,ratio between CD4+ and CD8+, CRP on day 0, 3, 7 after the start of the infusion in both groups.
Time frame: 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.